DK3386997T3 - Monomaleimid-funktionaliserede platinforbindelser til cancerterapi - Google Patents

Monomaleimid-funktionaliserede platinforbindelser til cancerterapi Download PDF

Info

Publication number
DK3386997T3
DK3386997T3 DK16822917.7T DK16822917T DK3386997T3 DK 3386997 T3 DK3386997 T3 DK 3386997T3 DK 16822917 T DK16822917 T DK 16822917T DK 3386997 T3 DK3386997 T3 DK 3386997T3
Authority
DK
Denmark
Prior art keywords
monomaleimide
cancer therapy
platinum compounds
functionalized platinum
functionalized
Prior art date
Application number
DK16822917.7T
Other languages
Danish (da)
English (en)
Inventor
Christian Kowol
Petra Heffeter
Walter Berger
Bernhard K Keppler
Josef Mayr
Verena Pichler
Original Assignee
Univ Wien Med
Univ Wien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med, Univ Wien filed Critical Univ Wien Med
Application granted granted Critical
Publication of DK3386997T3 publication Critical patent/DK3386997T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086Platinum compounds
    • C07F15/0093Platinum compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16822917.7T 2015-12-09 2016-12-09 Monomaleimid-funktionaliserede platinforbindelser til cancerterapi DK3386997T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15198739 2015-12-09
PCT/EP2016/080453 WO2017097986A1 (en) 2015-12-09 2016-12-09 Monomaleimide-functionalized platinum compounds for cancer therapy

Publications (1)

Publication Number Publication Date
DK3386997T3 true DK3386997T3 (da) 2021-09-20

Family

ID=54849106

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16822917.7T DK3386997T3 (da) 2015-12-09 2016-12-09 Monomaleimid-funktionaliserede platinforbindelser til cancerterapi

Country Status (21)

Country Link
US (2) US10723748B2 (OSRAM)
EP (1) EP3386997B1 (OSRAM)
JP (1) JP6867652B2 (OSRAM)
CN (1) CN108368143B (OSRAM)
AU (1) AU2016367306B2 (OSRAM)
CA (1) CA3004630A1 (OSRAM)
CY (1) CY1124529T1 (OSRAM)
DK (1) DK3386997T3 (OSRAM)
ES (1) ES2898704T3 (OSRAM)
HR (1) HRP20211466T1 (OSRAM)
HU (1) HUE056897T2 (OSRAM)
IL (1) IL259864B (OSRAM)
LT (1) LT3386997T (OSRAM)
MX (1) MX377528B (OSRAM)
PL (1) PL3386997T3 (OSRAM)
PT (1) PT3386997T (OSRAM)
RS (1) RS62412B1 (OSRAM)
SG (1) SG11201804885TA (OSRAM)
SI (1) SI3386997T1 (OSRAM)
SM (1) SMT202100709T1 (OSRAM)
WO (1) WO2017097986A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015200250A1 (en) * 2014-06-23 2015-12-30 Blend Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
CN109171001A (zh) * 2018-09-14 2019-01-11 上海烟草集团有限责任公司 草酸钠在降低卷烟烟气中TSNAs释放量中的应用
EP4085053A4 (en) * 2019-12-31 2023-12-27 Kinnate Biopharma Inc. TREATING CANCER WITH CDK12/13 INHIBITORS
CN114163479B (zh) * 2020-09-11 2025-05-16 上海海聚生物科技有限公司 一类治疗癌症用的铂类化合物及其制备方法
US20230339997A1 (en) * 2020-09-11 2023-10-26 Shanghai Haiju Biological Technology Co., Ltd. Class of platinum compounds for treating cancer, and method for preparation thereof
CN114539320A (zh) * 2020-11-25 2022-05-27 北京大学 辐射激活的四价铂配合物及其用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH605550A5 (OSRAM) 1972-06-08 1978-09-29 Research Corp
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS607934A (ja) 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソ−ムの製造方法
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3486459D1 (de) 1983-09-26 1997-12-11 Udo Dr Med Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
CS269719B1 (en) 1986-12-29 1990-05-14 Kiss Frantisek Platinum cytostatic
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
KR100575070B1 (ko) 1997-09-29 2006-05-03 넥타르 테라퓨틱스 안정화된 생활성 제제 및 이의 사용 방법
JP4169478B2 (ja) 1998-04-21 2008-10-22 マイクロメット アーゲー Cd19×cd3特異的ポリペプチドおよびその使用
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
AUPQ641100A0 (en) 2000-03-23 2000-04-15 Australia Nuclear Science & Technology Organisation Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
DE10314780A1 (de) 2003-03-19 2004-09-30 Ktb Tumorforschungsgesellschaft Mbh Proteinbindende Derivate von Platinkomplexen mit Cyclobutan-1,1-dicarboxylatliganden
EP1608358A1 (en) 2003-03-31 2005-12-28 Pliva-Lachema A.S. Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
CZ296169B6 (cs) 2004-09-08 2006-01-11 Pliva - Lachema A. S. Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
CZ296459B6 (cs) 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
US20060205810A1 (en) 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
CZ300590B6 (cs) 2006-06-20 2009-06-24 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
CZ300424B6 (cs) 2006-06-20 2009-05-13 Pliva - Lachema A. S. Farmaceutická kompozice pro perorální podání
CZ300120B6 (cs) 2006-06-20 2009-02-11 Pliva - Lachema A. S. Farmaceutická kompozice pro injekcní podání
WO2013085925A1 (en) 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
MX366864B (es) * 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
WO2015052516A1 (en) * 2013-10-08 2015-04-16 Atlas Genetics Limited Labelling compounds and their use in assays
WO2015102922A1 (en) * 2013-12-31 2015-07-09 Blend Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
WO2015200250A1 (en) * 2014-06-23 2015-12-30 Blend Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
EP3313393A4 (en) 2015-06-23 2019-01-09 Placon Therapeutics, Inc. PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF
WO2016209918A1 (en) 2015-06-23 2016-12-29 Placon Therapeutics, Inc. Platinum compounds, compositions, and uses thereof
EP3313527B1 (en) 2015-06-29 2021-02-24 Case Western Reserve University Anticancer drug-containing plant virus particles
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
EP3482205A1 (en) 2016-07-08 2019-05-15 H. Hoffnabb-La Roche Ag Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
WO2018026742A1 (en) 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
CN108164512B (zh) 2017-12-27 2021-05-25 沈阳药科大学 一类具有生物粘附作用的马来酰亚胺型前药及其在口服药物传递中的应用
CN108187063B (zh) 2018-01-09 2020-09-08 沈阳药科大学 白蛋白结合型抗肿瘤药-马来酰亚胺分子前药

Also Published As

Publication number Publication date
IL259864A (en) 2018-07-31
LT3386997T (lt) 2021-12-10
CN108368143A (zh) 2018-08-03
SI3386997T1 (sl) 2021-11-30
SMT202100709T1 (it) 2022-01-10
AU2016367306A1 (en) 2018-06-14
HUE056897T2 (hu) 2022-03-28
JP6867652B2 (ja) 2021-05-12
CN108368143B (zh) 2022-02-01
MX377528B (es) 2025-03-10
MX2018006953A (es) 2019-05-16
EP3386997A1 (en) 2018-10-17
PL3386997T3 (pl) 2021-12-13
US20210002313A1 (en) 2021-01-07
US11572379B2 (en) 2023-02-07
EP3386997B1 (en) 2021-06-30
ES2898704T3 (es) 2022-03-08
PT3386997T (pt) 2021-11-04
US20180354979A1 (en) 2018-12-13
CY1124529T1 (el) 2022-07-22
WO2017097986A1 (en) 2017-06-15
CA3004630A1 (en) 2017-06-15
AU2016367306B2 (en) 2021-04-22
US10723748B2 (en) 2020-07-28
SG11201804885TA (en) 2018-07-30
JP2018538292A (ja) 2018-12-27
RS62412B1 (sr) 2021-10-29
IL259864B (en) 2022-07-01
HRP20211466T1 (hr) 2021-12-24

Similar Documents

Publication Publication Date Title
IL255261A0 (en) Methods for treating cancer
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
PT3283527T (pt) Terapêutica de combinação para o cancro
DK3389778T3 (da) Indretning til fotodynamisk behandling
EP3314027A4 (en) THERAPEUTIC OLIGONUCLEOTIDES
DK3119808T3 (da) Antistofsammensætninger til tumorbehandling
HUE054012T2 (hu) Kombinációs terápia rák ellen
DK3288581T3 (da) Fremgangsmåde til behandling af cancer
DK3265421T3 (da) Doseringssystem
DK3171929T3 (da) Dosering til nervestimulation
HUE059694T2 (hu) Készítmény rák kezelésére
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3253382T3 (da) Farmaceutiske sammensætninger til kombinationsterapi
DK3262066T4 (da) Genterapi
KR20180084772A (ko) 암 치료를 위한 조합 치료법
PL3622953T3 (pl) Leczenie skojarzone nowotworu
DK3386997T3 (da) Monomaleimid-funktionaliserede platinforbindelser til cancerterapi
EP3413927A4 (en) CANCER THERAPY
HUE040167T2 (hu) Rákkezelés
DK3393478T3 (da) Kombinationsterapi
DK3383385T3 (da) Melflufen-doseringsregimer for cancer
EP3362091A4 (en) COMBINATION THERAPY
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
DK3374357T3 (da) Disubstituerede diaryloxybenzoheterodiazol-forbindelser
DK3329004T3 (da) Terapeutiske oligonukleotider